82 results
8-K
EX-99.1
ENTA
Enanta Pharmaceuticals Inc
6 May 24
Results of Operations and Financial Condition
4:05pm
Healthcare Conference, June 5, 2024
Enanta plans to issue its fiscal third quarter financial results press release on August 5, 2024.
Conference Call
8-K
EX-99.1
ENTA
Enanta Pharmaceuticals Inc
7 Feb 24
Enrollment Ongoing Across Three RSV Phase 2 Studies; Anticipates Announcing Topline Data for RSVPEDs and EDP-323 Challenge Study in Q3 2024
4:05pm
, as well as plans to introduce a second immunology program in 2024.
Upcoming Events
Oppenheimer 34th Annual Healthcare Life Sciences Conference
8-K
EX-99.1
s4iizda9g6mjhtar7u
20 Nov 23
Results of Operations and Financial Condition
4:05pm
8-K
EX-99.1
f816cos67z7t38xv04v
7 Aug 23
Results of Operations and Financial Condition
4:06pm
8-K
EX-99.1
dxkybvirxzn0ov rr
7 Jun 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
81yy0il1sxrfxun04h8
8 May 23
Strengthened Balance Sheet Through the Sale of 54.5% of Future MAVYRET®/MAVIRET® Royalties for an Upfront Payment of $200 Million
4:06pm
8-K
EX-99.1
cs9qm6m7fl7gtv8g
21 Nov 22
Results of Operations and Financial Condition
4:08pm
8-K
EX-1.1
epilunx3u9dj7bndikez
26 Aug 22
Entry into a Material Definitive Agreement
4:10pm
8-K
EX-99.1
uon01x6qc4ncd i2fu
8 Aug 22
Results of Operations and Financial Condition
4:04pm
8-K
EX-99.1
kv3eyctn
22 Nov 21
Results of Operations and Financial Condition
4:05pm